Note: This study is currently only recruiting patients in the hospital.

If you are interested in being notified if this study begins recruiting from the general population, please use the 'I Am Interested' button below.

ARRIVAL: Asthma study to see if taking FDA approved Tezepelumab can help lower inhaler use

ARRIVAL is a Phase IIIb open-label study researching the already FDA-approved biologic treatment, TEZSPIRE. Complete our survey & see if you're eligible to participate in our studies: https://redcap.partners.org/redcap/surveys/?s=kbwtYE

Brigham and Women's Hospital Clinical Trials Lung Diseases Asthma
20 visits over 18 months
Estimated Time Commitment
Any Sex/Gender, 18-80 years
May Be Eligible
Payment up to $2,200
May Be Offered
Survey, Personal health tracking, Blood draw, Injection or IV, Medication, Office visit, Biosample (e.g., saliva, urine, or stool)
May Be Required
 
I Am Interested I Am Interested I Am Interested

Enrollment for this study is expected to close on Saturday, June 14, 2025

Overview

What we are studying

This Phase IIIb clinical research study is examining the FDA-approved drug Tezspire (Tezepelumab) in people with severe asthma.  This is an open-label study so all eligible participants will be able to try Tezepelumab. The study aims to see if monthly injections of this biologic medication might allow asthma patients to reduce the use of their daily background controller inhalers.


Why it is important

The study team is looking to understand if treatment with Tezepelumab in patients with severe asthma could meaningully improve asthma symptoms and allow certain patients to decrease their inhaler use.


What we hope to accomplish

Administration of Tezepelumab to patients with severe asthma  could result in a meaningful reduction in asthma attcaks, improvement in lung fuction and improvement in asthma control.

Principal Investigator

Elliot Israel, MD

Brigham and Women's Hospital

Public Profile

Contact

Click I Am Interested "I Am Interested" "I Am Interested" to get started. If you have questions, contact:

Eren

egulbas@bwh.harvard.edu
(617) 525-8034

Asthma Research Center

arc@partners.org
(617) 732-8201

Who can participate


  • Are age 18-80

  • Have been diagnosed with asthma

  • Have a documented history of at least 1 asthma exacerbation within 12 months 

  • Are on a stable regimen of asthma medications that includes medications such as Advair/Wixela, Symbicort, Breo, or Dulera

  • Are not pregnant and not breastfeeding

  • Are not taking part in other clinical trials

Who cannot participate


  • People who have chronic obstructive pulmonary disease or another significant lung disease

  • People who are currently being treated with immunosuppressive or immunomodulatory drugs for a disease other than asthma

  • People who are pregnant or breastfeeding

What you may be asked to do


  • Physical Exam

  • Questionnaires

  • Blood draw

  • Spirometry

  • Vital signs

  • Using the study-provided Inhalers

  • Administration of the study drug via injection


Project activities may include:

  • Survey
  • Personal health tracking
  • Blood draw
  • Injection or IV
  • Medication
  • Office visit
  • Biosample (e.g., saliva, urine, or stool)

Estimated Time Commitment

20 visits over 18 months

What You May Get

Participants will have at least 20 visits over an 18-month period. The study team will provide the Tezepelumab study drug at no cost. All participants will start the study using their own inhalers, but after a few months of injections they will be switched to Symbicort and Airsupra at no cost. Participants will be compensated up to $2200.

Location

Brigham and Women's Hospital
75 Francis Street; Boston, MA

Map it!


Travel

  • Accessible by public transportation
  • Parking reimbursed
  • Parking available

Travel and Parking Details

Vouchers will be provided to cover parking at BWH garages during study visits.

Additional Information

Project Website

https://www.asthmabwh.org/


ClinicalTrials.gov Identifier

NCT06473779


Study Phase

Phase 3: This project studies a drug or treatment that has already been studied for safety and effectiveness in both healthy volunteers and participants with specific diseases or conditions. It will gather more information about safety and effectiveness. It may look specifically at different groups of people, different dosages, or different combinations of medications or treatments.


Participating Institutions


Funding Source

  • Industry
Top